Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Spectral AI’s DeepView System has demonstrated successful results in US burn validation studies and received FDA Breakthrough Device Designation. The company anticipates its first commercial product revenue in the second half of 2025 and plans to submit regulatory filings for approval of the burn indication in the US during H1 2025. The platform aims to provide immediate wound healing predictions using multispectral imaging and proprietary artificial intelligence algorithms.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Spectral AI.